Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG

Journal of Neuroimmune Pharmacology

Volumn 5, Issue 2, 2010, Pages 231-239

  Sinha, Sushmita ^a,b   Subramanian, Sandhya ^a   Emerson Webber, Ashley ^c   Lindner, Maren ^d   Burrows, Gregory G ^b,e   Grafe, Marjorie ^b   Linington, Christopher ^d   Vandenbark, Arthur A ^a,b,e   Bernard, Claude C A ^c   Offner, Halina ^a,b,e  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CNS damage; EAE; MS; Recombinant human MOG

Indexed keywords

ANTIHISTAMINIC AGENT; AUTOANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RECOMBINANT HUMAN MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RECOMBINANT PROTEIN; RECOMBINANT RECEPTOR; RECOMBINANT T LYMPHOCYTE RECEPTOR LIGAND 551; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; AXONAL INJURY; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; MALE; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CYTOKINES; DEMYELINATING DISEASES; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MYELIN-ASSOCIATED GLYCOPROTEIN; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS;

EID: 77954562729     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-009-9175-1     Document Type: Article

References (22)

1. Bruck W, Lucchinetti C, Lassmann H (2002) The pathology of primary progressive multiple sclerosis. Mult Scler 8:93-97
2. Burrows GG, Bebo BF Jr, Adlard KL, Vandenbark AA, Offner H (1998) Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. J Immunol 161:5987-5996
3. Burrows GG, Chou YK, Wang C, Chang JW, Finn TP, Culbertson NE, Kim J, Bourdette DN, Lewinsohn DA, Lewinsohn DM, Ikeda M, Yoshioka T, Allen CN, Offner H, Vandenbark AA (2001) Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J Immunol 167:4386-4395
4. Chan J, Ban EJ, Chun KH, Wang S, McQualter J, Bernard C, Toh BH, Alderuccio F (2008) Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 41:405-413
5. Chang JW, Mechling DE, Bachinger HP, Burrows GG (2001) Design, engineering, and production of human recombinant T cell receptor ligands derived from human leukocyte antigen DR2. J Biol Chem 276:24170-24176
6. Chou YK, Culbertson N, Rich C, LaTocha D, Buenafe AC, Huan J, Link J, Wands JM, Born WK, Offner H, Bourdette DN, Burrows GG, Vandenbark AA (2004) T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. J Neurosci Res 77:670-680
7. Haines JL et al (1996) A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 13:469-471
8. Hauser SL (2008) Multiple lessons for multiple sclerosis. N Engl J Med 359:1838-1841
9. Huan J, Subramanian S, Jones R, Rich C, Link J, Mooney J, Bourdette DN, Vandenbark AA, Burrows GG, Offner H (2004) Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J Immunol 172:4556-4566
10. Kieseier BC, Hartung HP (2003) Current disease-modifying therapies in multiple sclerosis. Semin Neurol 23:133-146
11. Lyons JA, Ramsbottom MJ, Cross AH (2002) Critical role of antigenspecific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol 32:1905-1913
12. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH (2005) Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 102:13992-13997
13. Merkler D, Schmelting B, Czeh B, Fuchs E, Stadelmann C, Bruck W (2006) Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult Scler 12:369-374
14. O'Connor KC et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211-217
15. Oliver AR, Lyon GM, Ruddle NH (2003) Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol 171:462-468
16. Pollinger B, Krishnamoorthy G, Berer K, Lassmann H, Bosl MR, Dunn R, Domingues HS, Holz A, Kurschus FC, Wekerle H (2009) Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOGspecific B cells. J Exp Med. doi:jem.20090299
17. Sinha S, Subramanian S, Proctor TM, Kaler LJ, Grafe M, Dahan R, Huan J, Vandenbark AA, Burrows GG, Offner H (2007) A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J Neurosci 27:12531-12539
18. Sinha S, Subramanian S, Miller L, Proctor TM, Roberts C, Burrows GG, Vandenbark AA, Offner H (2009) Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand. J Neurosci 29:3816-3823
19. Storch M, Lassmann H (1997) Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 10:1838-1841
20. Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, Huan J, Fugger L, Offner H, Jones R, Burrows GG (2003) Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLADR2 transgenic mice. J Immunol 171:127-133
21. Wang C, Mooney JL, Meza-Romero R, Chou YK, Huan J, Vandenbark AA, Offner H, Burrows GG (2003) Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol 171:1934-1940
22. Wang C, Gold BG, Kaler LJ, Yu X, Afentoulis ME, Burrows GG, Vandenbark AA, Bourdette DN, Offner H (2006) Antigenspecific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 98:1817-1827